Dementia in Parkinson’s Disease and Central Cholinergic Function

  • Klaus W. Lange
  • Peter Jenner
  • C. David Marsden
Part of the Advances in Behavioral Biology book series (ABBI, volume 38A)


Dementia occurs in a significant number of patients with Parkinson’s disease without substantial pathological changes typical of Alzheimer’s disease, i.e. they do not show a higher number of senile plaques and neurofibrillary tangles in the cerebral cortex than those expected by age alone (Candy et al., 1983; Perry et al., 1985). While much is known about the central biochemical changes causing the movement disorders in Parkinsonian subjects (Agid et al., 1989), the neurochemical basis of cognitive impairment and dementia is less clear.


Muscarinic Receptor Temporal Cortex Cholinergic System Muscarinic Cholinergic Receptor Choline Acetyltransferase Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Agid, Y., Cervera, P., Hirsch, E., Javoy-Agid, F., Lehericy, S., Raisman, R., and Ruberg, M., 1989, Biochemistry of Parkinson’s disease 28 years later: A critical review, Movement Disorders, 4: S 126.CrossRefGoogle Scholar
  2. Bradford, M., 1976, A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding, Anal. Biochem., 72: 248–254.PubMedCrossRefGoogle Scholar
  3. Brown, R.G., Marsden, C.D., Quinn, N., and Wyke, M., 1984, Alterations in cognitive performance and affect-arousal state during fluctuations in motor function in Parkinson’s disease, J. Neurol. Neurosurg. Psychiat., 47: 454.PubMedCrossRefGoogle Scholar
  4. Candy, J.M., Perry, R.H., Perry, E.K., Irving, D., Blessed, G., Fairbairn, A.F., and Tomlinson, B.E., 1983, Pathological changes in the nucleus of Meynert in Alzheimer’s and Parkinson’s diseases, J. Neurol. Sci., 54: 277.CrossRefGoogle Scholar
  5. De Smet, Y., Ruberg, M., Serdaru, M., Dubois, B., Lhermitte, F., and Agid, Y., 1982, Confusion, dementia and anticholinergics in Parkinson’s disease, J. Neurol. Neurosurg. Psychiat., 45: 1161.PubMedCrossRefGoogle Scholar
  6. Dubois, B., Danzé, F., Pillon, B., Cusimano, G., Lhermitte, F., and Agid Y., 1987, Cholinergic-dependent cognitive defects in Parkinson’s disease, Ann. Neurol., 22: 26.PubMedCrossRefGoogle Scholar
  7. Dubois, B., Hauw, J.J., Ruberg, M., Serdaru, M., Javoy-Agid, F., and Agid, Y., 1985, Démence et maladie de Parkinson: corrélations biochimiques et anatomo-cliniques, Rev. Neurol., 141: 184.PubMedGoogle Scholar
  8. Dubois, B., Ruberg, M., Javoy-Agid, F., Ploska, A., and Agid, Y., 1983, A subcortico- cortical cholinergic system is affected in Parkinson’s disease, Brain Res., 288: 213.PubMedCrossRefGoogle Scholar
  9. Fonnum, F., 1975, A rapid radiochemical method for the determination of choline acetyltransferase, J. Neurochem., 24: 407.PubMedCrossRefGoogle Scholar
  10. Hornykiewicz, O., 1982, Brain neurotransmitter changes in Parkinson’s disease, in: “Movement Disorders”, C.D. Marsden and S. Fahn, eds., Butterworths, London.Google Scholar
  11. Lange, K.W., Wells, F.R., Rossor, M.N., Jenner, P., and Marsden, C.D., 1989, Brain muscarinic receptors in Alzheimer’s and Parkinson’s diseases, Lancet, 11: 1279.CrossRefGoogle Scholar
  12. Loranger, A.W., Goodell, H., Lee, J.E., and McDowell, F., 1972, Levodopa treatment of Parkinson’s syndrome: Improved intellectual functioning, Arch. Gen. Psychiatry, 26: 163.PubMedCrossRefGoogle Scholar
  13. Mash, D.C., Flynn, D.D., and Potter, L.T., 1985, Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer’s disease and experimental cholinergic denervation, Science, 228: 1115.PubMedCrossRefGoogle Scholar
  14. Mortimer, J.A., Pirozzolo, F.J., Hansch, E.C., and Webster, D.D., 1982, Relationship of motor symptoms to intellectual deficits in Parkinson’s disease, Neurology, 32: 133.PubMedCrossRefGoogle Scholar
  15. Nakano, I., and Hirano, A., 1984, Parkinson’s disease: Neuron loss in the nucleus basalis without concomitant Alzheimer’s disease, Ann. Neurol., 15, 415.PubMedCrossRefGoogle Scholar
  16. Perry, E.K., Curtis, M., Dick, D.J., Candy, J.M., Atack, J.R., Bloxham, C.A., Blessed, G., Fairbairn, A., Tomlinson, B.E., and Perry, R.H., 1985, Cholinergic correlates of cognitive impairment in Parkinson’s disease: comparison with Alzheimer’s disease, J. Neurol. Neurosurg. Psychiat., 48: 413.PubMedCrossRefGoogle Scholar
  17. Perry, E.K., Tomlinson, B.E., Blessed, G., Bergmann, K., Gibson, P.H., and Perry, R.H., 1978, Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia, Br. Med. J., 11: 1457.CrossRefGoogle Scholar
  18. Pillon, B., Dubois, B., Cusimano, G., Bonnet, A.-M., Lhermitte, F., and Agid, Y. (1989). Does cognitive impairment in Parkinson’s disease result from non-dopaminergic lesions? J. Neurol. Neurosurg. Psychiat., 52: 201.PubMedCrossRefGoogle Scholar
  19. Rinne, J.O., Laakso, K., Lönnberg, P., Mölsä, P., Paljärvi, L., Rinne, J.K., Säkö, E., and Rinne, U.K., 1985, Brain muscarinic receptors in senile dementia, Brain Res., 336: 19.PubMedCrossRefGoogle Scholar
  20. Ruberg, M., Ploska, A., Javoy-Agid, F., and Agid, Y, 1982, Muscarinic binding and choline acetyltransferase activity in Parkinsonian subjects with reference to dementia, Brain Res., 232: 129.PubMedCrossRefGoogle Scholar
  21. Scatton, B., Javoy-Agid, F., Rouquier, L., Dubois, B., and Agid, Y., 1983, Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson’s disease, Brain Res., 275: 321.PubMedCrossRefGoogle Scholar
  22. Shimohama, S., Taniguchi, T., Fujiwara, M., and Kameyama, M., 1986, Changes in nicotinic and muscarinic cholinergic receptors in Alzheimer-type dementia, J. Neurochem., 46: 288.PubMedCrossRefGoogle Scholar
  23. Westlind, A., Grynfarb, M., Hedlund, B., Bartfai, T., and Fuxe, K., 1981, Muscarinic supersensitivity induced by septal lesion or chronic atropine treatment. Brain Res., 225: 131.PubMedCrossRefGoogle Scholar
  24. Whitehouse, P.J., Hedreen, J.C., White III, C.L., and Price, D.L., 1983, Basal forebrain neurons in the dementia of Parkinson’s disease, Ann. Neurol. 13: 243.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1990

Authors and Affiliations

  • Klaus W. Lange
    • 1
    • 2
  • Peter Jenner
    • 1
    • 2
  • C. David Marsden
    • 1
    • 2
  1. 1.University Department of Neurology and Parkinson’s Disease Society Research Centre, Institute of PsychiatryKing’s College School of MedicineLondonUK
  2. 2.University Department of Clinical Neurology, Institute of NeurologyThe National HospitalLondonUK

Personalised recommendations